EVX020
Hematologic Malignancies (as ADC payload)
Key Facts
About Evexta Bio
Evexta Bio is a Paris-based, clinical-stage biotechnology company founded in 2019, developing novel oncology therapeutics. Its lead asset, rupitasertib, is a first-in-class oral dual inhibitor of the PAM pathway (targeting S6K and AKT1/3) aimed at overcoming treatment resistance in advanced breast cancer, currently in Phase 1. The second program, EVX020, is a first-in-class KIF20A inhibitor being developed as an antibody-drug conjugate (ADC) payload for hematological and solid tumors. The company is backed by Truffle Capital and has established key partnerships with institutions like CNRS and Merck KGaA.
View full company profileAbout Evexta Bio
Evexta Bio is a Paris-based, clinical-stage biotechnology company founded in 2019, developing novel oncology therapeutics. Its lead asset, rupitasertib, is a first-in-class oral dual inhibitor of the PAM pathway (targeting S6K and AKT1/3) aimed at overcoming treatment resistance in advanced breast cancer, currently in Phase 1. The second program, EVX020, is a first-in-class KIF20A inhibitor being developed as an antibody-drug conjugate (ADC) payload for hematological and solid tumors. The company is backed by Truffle Capital and has established key partnerships with institutions like CNRS and Merck KGaA.
View full company profile